Article citationsMore>>

Y. Wu, K. Tang, R. Q. Huang, Z. Zhuang, H. L. Cheng, H. X. Yin and J. X. Shi, “Therapeutic Potential of peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone in Cerebral Vasospasm after a Rat Experimental Subarachnoid Hemorrhage Model,” Journal of the Neurological Sciences, Vol. 305, No. 1-2, 2011, pp. 85-91. http://dx.doi.org/10.1016/j.jns.2011.03.006

has been cited by the following article:

• TITLE: New Developments in Drug Therapy and Research of Cerebral Vasospasm

  AUTHORS: Eleftherios Archavlis, Peter Ulrich, Mario Carvi Y. Nievas

  KEYWORDS: Cerebral Vasospasm; Drug Therapy; Subarachnoid Hemorrhage; Delayed Cerebral Ischemia; New Developments; Treatment

  JOURNAL NAME: Open Journal of Modern Neurosurgery, Vol.3 No.4, October 15, 2013

  ABSTRACT: In this manuscript a comprehensive coverage of recent developments in the drug therapy of vasospasm while providing the background information that neuroscientists need to understand its rationale. The range of new agents available for treatment of cerebral vasospasm is expanding rapidly along with rapid advances in pharmacology and physiology that are uncovering the mechanisms of this disease. Although there are many publications for treatment of cerebral vaso-spasm, most are focusing on different aspects of vasospasm treatment and many have limited value due to insufficient quality. Moreover, the complexity of this, in many cases deleterious condition, is enormous and the information needed to understand drug effects is accordingly often not readily available in a single source. A number of pharmacological and medical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Current research efforts promise the eventual production of new medical therapies. At last, recommendations for the use of different treatment stages based on currently available clinical data are provided.